Diagnosis and management of natural killer-cell malignancies

References

• Spits H, Lanier LL, Phillips JH. Development of human T and natural killer cells. Blood85, 2654–2670 (1995).
   PubMed Web of Science ®Google Scholar
• Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia19, 2186–2194 (2005).
   PubMed Web of Science ®Google Scholar
• Lanier LL, Testi R, Bindl J, Phillips JH. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J. Exp. Med.169, 2233–2238 (1989).
   PubMed Web of Science ®Google Scholar
• Byrd LJ, Shearn MA, Tu WH. Relationship of lethal midline granuloma to Wegener’s granulomatosis. Arthritis Rheum.12, 247–253 (1969).
   PubMedGoogle Scholar
• Batsakis JG, Luna MA. Midfacial necrotizing lesions. Semin. Diagn. Pathol.4, 90–116 (1987).
   PubMed Web of Science ®Google Scholar
• Eichel BS, Harrison EG Jr, Devine KD, Scanlon PW, Brown HA. Primary lymphoma of the nose including a relationship to lethal midline granuloma. Am. J. Surg.112, 597–605 (1966).
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Stein H et al. A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood84(5), 1361–1392 (1994).
   PubMed Web of Science ®Google Scholar
• Wong KF, Chan JK, Ng CS, Lee KC, Tsang WY, Cheung MM. CD56 (NKH1)-positive hematolymphoid malignancies: an aggressive neoplasm featuring frequent cutaneous/mucosal involvement, cytoplasmic azurophilic granules, and angiocentricity. Hum. Pathol.23, 798–804 (1992).
   PubMed Web of Science ®Google Scholar
• Chan JK, Tsang WY, Ng CS. Clarification of CD3 immunoreactivity in nasal T/natural killer cell lymphomas: the neoplastic cells are often CD3ε+. Blood87, 839–841 (1996).
   PubMed Web of Science ®Google Scholar
• Chan JK, Quintanilla-Martinez L, Ferry JA, Peh SC. Extranodal NK/T-cell lymphoma, nasal type. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL et al. (Eds). International Agency for Research on Cancer, Lyon, France 285–288 (2008).
   Google Scholar
• Au WY, Ma SY, Chim CS et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann. Oncol.16, 206–214 (2005).
   PubMed Web of Science ®Google Scholar
• Chan JK, Yip TT, Tsang WY et al. Detection of Epstein–Barr viral RNA in malignant lymphomas of the upper aerodigestive tract. Am. J. Surg. Pathol.18, 938–946 (1994).
   PubMed Web of Science ®Google Scholar
• Cohen JI, Kimura H, Nakamura S, Ko YH, Jaffe ES. Epstein–Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8–9 September 2008. Ann. Oncol.20, 1472–1482 (2009).
   PubMed Web of Science ®Google Scholar
• Chan JK, Jaffe ES, Ralfkiaer E, Ko YH. Aggressive NK-cell leukaemia. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL et al. (Eds). International Agency for Research on Cancer, Lyon, France 276–277 (2008).
   Google Scholar
• Kwong YL, Chan AC, Liang RH. Natural killer cell lymphoma/leukemia: pathology and treatment. Hematol. Oncol.15, 71–79 (1997).
   PubMed Web of Science ®Google Scholar
• Cheung MM, Chan JK, Lau WH et al. Primary non-Hodgkin’s lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J. Clin. Oncol.16, 70–77 (1998).
   PubMed Web of Science ®Google Scholar
• Chan JK, Sin VC, Wong KF et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood89, 4501–4513 (1997).
   PubMed Web of Science ®Google Scholar
• Suzuki R, Suzumiya J, Nakamura S et al.; NK-cell Tumor Study Group. Aggressive natural killer-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia18, 763–770 (2004).
   PubMed Web of Science ®Google Scholar
• Kwong YL, Chan AC, Liang R et al. CD56+ NK lymphomas: clinicopathological features and prognosis. Br. J. Haematol.97, 821–829 (1997).
   PubMed Web of Science ®Google Scholar
• Wong KF, Chan JK, Cheung MM, So JC. Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon. Am. J. Clin. Pathol.115, 266–270 (2001).
   PubMed Web of Science ®Google Scholar
• Kim GE, Cho JH, Yang WI et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J. Clin. Oncol.18, 54–63 (2000).
   PubMed Web of Science ®Google Scholar
• Chim CS, Ma ES, Loong F, Kwong YL. Diagnostic cues for natural killer cell lymphoma: primary nodal presentation and the role of in situ hybridisation for Epstein–Barr virus encoded early small RNA in detecting occult bone marrow involvement. J. Clin. Pathol.58, 443–445 (2005).
   PubMed Web of Science ®Google Scholar
• Khong PL, Pang CB, Liang R, Kwong YL, Au WY. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies. Ann. Hematol.87, 613–621 (2008).
   PubMed Web of Science ®Google Scholar
• Au WY, Pang A, Choy C, Chim CS, Kwong YL. Quantification of circulating Epstein–Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood104, 243–249 (2004).
   PubMed Web of Science ®Google Scholar
• Chim CS, Ma SY, Au WY et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood103, 216–221 (2004).
   PubMed Web of Science ®Google Scholar
• Lee J, Suh C, Park YH et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J. Clin. Oncol.24, 612–618 (2006).
   PubMed Web of Science ®Google Scholar
• Suzuki R, Suzumiya J, Yamaguchi M et al.; for The NK-cell Tumor Study Group. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type. Ann. Oncol.21, 1032–1040 (2010).
   PubMed Web of Science ®Google Scholar
• Kwong YL, Anderson BO, Advani R, Kim WS, Levine AM, Lim ST. Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol.10, 1093–1101 (2009).
   PubMed Web of Science ®Google Scholar
• Au WY, Weisenburger DD, Intragumtornchai T et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the international peripheral T-cell lymphoma project. Blood113, 3931–3937 (2009).
   PubMed Web of Science ®Google Scholar
• Isobe K, Uno T, Tamaru J et al. Extranodal natural killer/T-cell lymphoma, nasal type: The significance of radiotherapeutic parameters. Cancer106, 609–615 (2006).
   PubMed Web of Science ®Google Scholar
• Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int. J. Radiat. Oncol. Biol. Phys.54, 182–190 (2002).
   PubMed Web of Science ®Google Scholar
• Tomita N, Kodaira T, Tachibana H et al. A comparison of radiation treatment plans using IMRT with helical tomotherapy and 3D conformal radiotherapy for nasal natural killer/T-cell lymphoma. Br. J. Radiol.82, 756–763 (2009).
   PubMed Web of Science ®Google Scholar
• Huang MJ, Jiang Y, Liu WP et al. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract. Int. J. Radiat. Oncol. Biol. Phys.70, 166–174 (2008).
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Tobinai K, Oguchi M et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group study JCOG0211. J. Clin. Oncol.27, 5594–5600 (2009).
   PubMed Web of Science ®Google Scholar
• Kim SJ, Kim K, Kim BS et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: Consortium for improving survival of lymphoma study. J. Clin. Oncol.27, 6027–6032 (2009).
   PubMed Web of Science ®Google Scholar
• Li YX, Liu QF, Fang H et al. Variable clinical presentations of nasal and waldeyer ring natural killer/T-cell lymphoma. Clin. Cancer Res.15, 2905–2912 (2009).
   PubMed Web of Science ®Google Scholar
• Yu JB, Zuo Z, Tang Y et al. Extranodal nasal-type natural killer/T-cell lymphoma of the skin: a clinicopathologic study of 16 cases in china. Hum. Pathol.40, 807–816 (2009).
   PubMed Web of Science ®Google Scholar
• Choi YL, Park JH, Namkung JH et al. Extranodal NK/T-cell lymphoma with cutaneous involvement: ‘nasal’ vs. ‘nasal-type’ subgroups – a retrospective study of 18 patients. Br. J. Dermatol.160, 333–337 (2009).
   PubMed Web of Science ®Google Scholar
• Tai WC, Li HP, Lin TY, Lin CY, Wu MT. Response of extranodal natural killer/T-cell lymphoma, nasal type, to interferon-a, corticosteroid and narrowband ultraviolet B phototherapy. Clin. Exp. Dermatol.34, e927–e930 (2009).
   PubMed Web of Science ®Google Scholar
• Kim WS, Song SY, Ahn YC et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann. Oncol.12, 349–352 (2001).
   PubMed Web of Science ®Google Scholar
• Lee SH, Ahn YC, Kim WS, Ko YH, Kim K, Park K. The effect of pre-irradiation dose intense CHOP on anthracyline resistance in localized nasal NK/T-cell lymphoma. Haematologica91, 427–428 (2006).
   PubMed Web of Science ®Google Scholar
• Lee KW, Yun T, Kim DW et al. First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. Leuk. Lymphoma47, 1274–1282 (2006).
   PubMed Web of Science ®Google Scholar
• Aviles A, Neri N, Fernandez R, Calva A, Huerta-Guzman J, Nambo MJ. Nasal NK/T-cell lymphoma with disseminated disease treated with aggressive combined therapy. Med. Oncol.20, 13–17 (2003).
   PubMed Web of Science ®Google Scholar
• Wang ZY, Li YX, Wang WH et al. Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents. Blood114, 4771–4776 (2009).
   PubMed Web of Science ®Google Scholar
• Ishida F, Nishina S, Asano N et al. Late relapse of extranodal natural killer/T cell lymphoma, nasal type, after more than ten years. Leuk. Lymphoma51, 171–173 (2010).
   PubMed Web of Science ®Google Scholar
• Au WY, Kim SJ, Yiu HH et al. Clinicopathological features and outcome of late relapses of natural killer cell lymphomas 10–29 years after initial remission. Am. J. Hematol.85, 362–363 (2010).
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Suzuki R, Kwong YL et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci.99, 1016–1020 (2008).
   PubMed Web of Science ®Google Scholar
• Kwong YL, Yamaguchi M, Maeda Y et al.; NK-cell Tumor Study Group. Phase II study of SMILE chemothearpy for newly-diagnosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type: NKTSG study. Haematologica95 (2010) (Abstract 0299).
   Google Scholar
• Jaccard A, Petit B, Girault S et al.L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann. Oncol.20, 110–116 (2009).
   PubMed Web of Science ®Google Scholar
• Yong W, Zheng W, Zhu J et al.L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann. Hematol.88, 647–652 (2009).
   PubMed Web of Science ®Google Scholar
• Kim BS, Kim DW, Im SA et al. Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone. Ann. Oncol.20, 121–128 (2009).
   PubMed Web of Science ®Google Scholar
• Lee J, Suh C, Kang HJ et al. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma. Ann. Oncol.19, 2079–2083 (2008).
   PubMed Web of Science ®Google Scholar
• Perrine SP, Hermine O, Small T et al. A Phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein–Barr virus-associated lymphoid malignancies. Blood109, 2571–2578 (2007).
   PubMed Web of Science ®Google Scholar
• Kwong YL. High-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignancies. Bone Marrow Transplant.44, 709–714 (2009).
   PubMed Web of Science ®Google Scholar
• Lee J, Au WY, Park MJ et al. Autologous hematopoietic stem cell transplantation in extranodal natural killer/T cell lymphoma: A multinational, multicenter, matched controlled study. Biol. Blood Marrow Transplant.14, 1356–1364 (2008).
   PubMed Web of Science ®Google Scholar
• Murashige N, Kami M, Kishi Y et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br. J. Haematol.130, 561–567 (2005).
   PubMed Web of Science ®Google Scholar
• Kako S, Izutsu K, Oshima K et al. Regression of the tumor after withdrawal of cyclosporine in relapsed extranodal natural killer/T cell lymphoma following allogeneic hematopoietic stem cell transplantation. Am. J. Hematol.82, 937–939 (2007).
   PubMed Web of Science ®Google Scholar
• Sato E, Ohga S, Kuroda H et al. Allogeneic hematopoietic stem cell transplantation for Epstein–Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan. Am. J. Hematol.83, 721–727 (2008).
   PubMed Web of Science ®Google Scholar
• Ito T, Makishima H, Nakazawa H et al. Promising approach for aggressive NK cell leukaemia with allogeneic haematopoietic cell transplantation. Eur. J. Haematol.81, 107–111 (2008).
   PubMed Web of Science ®Google Scholar